• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Results of a multicentre UK-wide compassionate use programme evaluating the efficacy of idelalisib monotherapy in relapsed, refractory follicular lymphoma.

作者信息

Eyre Toby A, Osborne Wendy L, Gallop-Evans Eve, Ardeshna Kirit M, Kassam Shireen, Sadullah Shalal, Sidra Gamal, Culligan Dominic, Arumainathan Arvind, Shankara Paneesha, Bowles Kristian M, Eyre David W, Peng Ying Y, Pettengell Ruth, Bloor Adrian, Vandenberghe Elisabeth, Collins Graham P

机构信息

Department of Haematology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Department of Haematology, Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne, UK.

出版信息

Br J Haematol. 2018 May;181(4):555-559. doi: 10.1111/bjh.14665. Epub 2017 Mar 24.

DOI:10.1111/bjh.14665
PMID:28342183
Abstract
摘要

相似文献

1
Results of a multicentre UK-wide compassionate use programme evaluating the efficacy of idelalisib monotherapy in relapsed, refractory follicular lymphoma.一项评估idelalisib单药疗法对复发难治性滤泡性淋巴瘤疗效的全英国多中心同情用药项目的结果。
Br J Haematol. 2018 May;181(4):555-559. doi: 10.1111/bjh.14665. Epub 2017 Mar 24.
2
Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy.idelalisib对高危滤泡性淋巴瘤及初始化学免疫治疗后早期复发的患者有效。
Blood. 2017 Jun 1;129(22):3037-3039. doi: 10.1182/blood-2016-12-757740. Epub 2017 Mar 21.
3
Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.idelalisib、来那度胺和利妥昔单抗在复发难治性淋巴瘤中的安全性和耐受性：肿瘤临床试验联盟A051201和A051202 1期试验
Lancet Haematol. 2017 Apr;4(4):e176-e182. doi: 10.1016/S2352-3026(17)30028-5. Epub 2017 Mar 15.
4
Phase 1b study to investigate the safety and tolerability of idelalisib in Japanese patients with relapsed/refractory follicular lymphoma and chronic lymphocytic leukemia.评估idelalisib 治疗复发/难治性滤泡性淋巴瘤和慢性淋巴细胞白血病日本患者的安全性和耐受性的 1b 期研究。
Jpn J Clin Oncol. 2020 Dec 16;50(12):1395-1402. doi: 10.1093/jjco/hyaa153.
5
Idelalisib for Treatment of Relapsed Follicular Lymphoma and Chronic Lymphocytic Leukemia: A Comparison of Treatment Outcomes in Clinical Trial Participants vs Medicare Beneficiaries.依鲁替尼治疗复发性滤泡性淋巴瘤和慢性淋巴细胞白血病：临床试验参与者与医疗保险受益人的治疗结果比较。
JAMA Oncol. 2020 Feb 1;6(2):248-254. doi: 10.1001/jamaoncol.2019.3994.
6
Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study.idelalisib治疗复发的、对利妥昔单抗和烷化剂难治的滤泡性淋巴瘤患者的疗效和安全性：一项2期研究的亚组分析
Haematologica. 2017 Apr;102(4):e156-e159. doi: 10.3324/haematol.2016.151738. Epub 2016 Dec 15.
7
Pharmacokinetics of idelalisib in chronic lymphocytic leukemia and follicular lymphoma disclose better outcomes for patients with lower exposure.idelalisib在慢性淋巴细胞白血病和滤泡性淋巴瘤中的药代动力学表明，暴露量较低的患者预后更佳。
Leuk Lymphoma. 2024 Sep;65(9):1378-1380. doi: 10.1080/10428194.2024.2353330. Epub 2024 May 15.
8
Management of psoriasis-like rash associated with idelalisib monotherapy in a patient with refractory follicular lymphoma: a case report.一名难治性滤泡性淋巴瘤患者接受idelalisib单药治疗时出现银屑病样皮疹的管理：病例报告
J Med Case Rep. 2020 Feb 24;14(1):35. doi: 10.1186/s13256-020-2344-9.
9
Idelalisib- a PI3Kδ targeting agent for B-cell malignancies.idelalisib——一种用于治疗B细胞恶性肿瘤的PI3Kδ靶向药物。
J Oncol Pharm Pract. 2016 Apr;22(2):284-8. doi: 10.1177/1078155215572933. Epub 2015 Feb 23.
10
Idelalisib for treatment of B-cell malignancies.idelalisib用于治疗B细胞恶性肿瘤。
Am J Health Syst Pharm. 2016 Apr 15;73(8):547-55. doi: 10.2146/ajhp150281. Epub 2016 Mar 1.

引用本文的文献

1
Old and New Drugs for Chronic Lymphocytic Leukemia: Lights and Shadows of Real-World Evidence.慢性淋巴细胞白血病的新旧药物：真实世界证据的亮点与阴影
J Clin Med. 2022 Apr 7;11(8):2076. doi: 10.3390/jcm11082076.
2
Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study.idelalisib治疗复发或难治性滤泡性淋巴瘤患者：意大利多中心观察性FolIdela研究
Cancers (Basel). 2022 Jan 27;14(3):654. doi: 10.3390/cancers14030654.
3
Novel Therapy Approaches to Follicular Lymphoma.
滤泡性淋巴瘤的新型治疗方法。
Drugs. 2021 Mar;81(4):453-469. doi: 10.1007/s40265-020-01446-1.
4
Controversies in the Treatment of Follicular Lymphoma.滤泡性淋巴瘤治疗中的争议
Hemasphere. 2020 Jan 10;4(1):e317. doi: 10.1097/HS9.0000000000000317. eCollection 2020 Feb.
5
Comprehensive Molecular Profiling for Relapsed/Refractory Pediatric Burkitt Lymphomas-Retrospective Analysis of Three Real-Life Clinical Cases-Addressing Issues on Randomization and Customization at the Bedside.复发/难治性儿童伯基特淋巴瘤的综合分子谱分析——三例真实临床病例的回顾性分析——探讨床边随机化和个体化问题
Front Oncol. 2020 Feb 7;9:1531. doi: 10.3389/fonc.2019.01531. eCollection 2019.